A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
预防淋病奈瑟菌感染的新型舌下疫苗
基本信息
- 批准号:10699065
- 负责人:
- 金额:$ 30.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-20 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdjuvantAdvanced DevelopmentAdverse eventAffectAgonistAluminumAnimalsAntibiotic ResistanceAntibiotic TherapyAntibioticsAntibodiesAntibody ResponseAntigensAreaBenchmarkingBiological AssayCefiximeCeftriaxoneCellsCephalosporinsCessation of lifeCiprofloxacinCold ChainsCommunicable DiseasesCommunitiesCoupledDataDoseDrug resistanceDrug-resistant Neisseria GonorrhoeaeEnvironmentEpitheliumFemaleFemale genitaliaFilmFormulationFundingFutureGoalsHumanImmuneImmune responseImmunizationImmunizeIndividualIndustryInfectionInfection ControlIntramuscularInvestmentsMeasuresMediatingModalityModelingMucosal Immune ResponsesMucosal ImmunityMucous MembraneMusNeisseria gonorrhoeaeNeisseria meningitidisNewborn InfantOralPelvic Inflammatory DiseasePenicillinsPersonsPharmacotherapyPhasePositioning AttributeProductionPropertyPublic HealthRecommendationResearchResourcesRouteSafetySelf AdministrationShippingSmall Business Innovation Research GrantSodium ChlorideSublingual drug administrationSurfaceSymptomsT cell responseTLR4 geneTestingTetracyclinesTranslatingVaccinationVaccine AdjuvantVaccinesWorkaluminum sulfateassaultcross reactivitydesigndrug developmentefficacy testingepidemiologic datagonorrhea vaccineimprovedindustry partnerinfection rateinnovationinterestlot productionlow and middle-income countriesmouse modelmucosal vaccinationnonhuman primatenovelnovel vaccinespathogenpreventprogramsreproductive tractresistant strainresponseside effectthermostabilityurogenital tractvaccine deliveryvaccine developmentvaccine efficacyvaccine formulationvaccinology
项目摘要
Project Summary
Our goal is to advance a novel, safe and effective sublingual (SL) vaccine against Neisseria gonorrhoeae (Ng)
infection.
Antibiotic resistant Ng is an interconnected global threat to people, animals, and the environment. Furthermore,
approximately 50% of all annual Ng infections in the US are drug-resistant1. The emergence of drug-resistant
Ng is accelerating, and previous antibiotic treatments such as penicillin, tetracycline, ciprofloxacin, and
cefixime are no longer recommended1, 2. A single recommended treatment remains – ceftriaxone. Current
research suggests that it is the suppression of Th1 and Th2 responses by Ng, modulated by increased Th17
responses, which drives Ng infection and re-infection3-5. Protection from Ng is thought to benefit from a robust
Th1 response or balanced Th1/Th2 response3, 6, 7. However, current Ng vaccination approaches mainly using
aluminum salt do not induce appropriate Th1/2 responses, limiting vaccine efficacy4, 8, 9. A vaccine that
generates a strong Th1, or a more balanced Th1/Th2 response, with robust mucosal immunity, would
significantly enhance Ng vaccine efficacy.
Current Ng vaccine approaches are mainly focused on developing novel parenteral vaccines4, 8. Parenteral
vaccines are generally effective at stimulating systemic antibody-mediated immune responses but are less
effective at inducing mucosal immunity10-12. Parenteral vaccines require significant resources for cold-chain
management and administration, which translate into slow global vaccination. Since low- and middle-income
countries have the highest Ng burden, new vaccines must support global delivery.
Our project team brings together three innovative aspects and areas of expertise that will make a novel SL Ng
vaccine a reality. First, we have identified novel Ng antigens expressed during natural mucosal infection that
generate cross-reactive antibody responses. Second, our novel TLR4 agonist, INI-2005, induces robust
systemic and mucosal immune response following SL administration. Third, INI-2005 demonstrates good
synthesis and thermostability properties and appears safe.
Building from this work, this application is designed to validate a SL Ng vaccine consisting of a novel SL
adjuvant, INI-2005, and three unique Ng antigens identified from a reverse vaccinology-like approach. The
specific aims of this Phase I SBIR application are to: 1) Produce and benchmark the TLR agonist and Ng
antigens; 2) Determine the optimal SL formulation to maximize immune responses in mice; and 3)
Demonstrate that the SL formulation effectively protects mice against Ng infection. Funding of this application
will validate a SL vaccine to prevent Ng infection, designed for robust Th1 immune responses and mucosal
immunity, administered easily, and thermostable for rapid, global distribution.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Neil A Fanger其他文献
Neil A Fanger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Neil A Fanger', 18)}}的其他基金
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
- 批准号:
10721794 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
一种治疗特发性肺纤维化的新型双特异性抗体
- 批准号:
10594937 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
- 批准号:
10600796 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Small Molecule for the Treatment of Periodontitis
一种治疗牙周炎的新型小分子
- 批准号:
10481054 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
一种治疗特发性肺纤维化的新型双特异性抗体
- 批准号:
10482438 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
- 批准号:
10706541 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
一种促进神经元完整性和神经发生的新型抗体,用于治疗阿尔茨海默病
- 批准号:
10893118 - 财政年份:2022
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease
用于早期检测阿尔茨海默病的新型多参数血液测试
- 批准号:
10570790 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease
一种用于早期检测阿尔茨海默病的新型多参数血液测试
- 批准号:
10491891 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease
一种用于早期检测阿尔茨海默病的新型多参数血液测试
- 批准号:
10683848 - 财政年份:2021
- 资助金额:
$ 30.65万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 30.65万 - 项目类别: